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Mechanisms of metabolic flexibility enable cells to
survive under stressful conditions and can thwart
therapeutic responses. Acetyl-coenzyme A (CoA)
plays central roles in energy production, lipid meta-
bolism, and epigenomic modifications. Here, we
show that, upon genetic deletion of Acly, the gene
coding for ATP-citrate lyase (ACLY), cells remain
viable and proliferate, although at an impaired rate.
In the absence of ACLY, cells upregulate ACSS2
and utilize exogenous acetate to provide acetyl-
CoA for de novo lipogenesis (DNL) and histone
acetylation. A physiological level of acetate is suffi-
cient for cell viability and abundant acetyl-CoA pro-
duction, although histone acetylation levels remain
low in ACLY-deficient cells unless supplemented
with high levels of acetate. ACLY-deficient adipo-
cytes accumulate lipid in vivo, exhibit increased
acetyl-CoA and malonyl-CoA production from ace-
tate, and display some differences in fatty acid con-
tent and synthesis. Together, these data indicate
that engagement of acetate metabolism is a crucial,
although partial, mechanism of compensation for
ACLY deficiency.INTRODUCTION
Acetyl-coenzyme A (CoA) is a central molecule in cell meta-
bolism, signaling, and epigenetics. It serves crucial roles in en-
ergy production, macromolecular biosynthesis, and protein
modification (Carrer and Wellen, 2015; Pietrocola et al., 2015).
Within mitochondria, acetyl-CoA is generated from pyruvate byCell Re
This is an open access article under the CC BY-Nthe pyruvate dehydrogenase complex (PDC), as well as from
catabolism of fatty acids and amino acids. To enter the tricarbox-
ylic acid (TCA) cycle, acetyl-CoA condenses with oxaloacetate,
producing citrate, a reaction catalyzed by citrate synthase.
Transfer of acetyl-CoA from mitochondria to the cytosol and nu-
cleus involves the export of citrate and its subsequent cleavage
by ATP-citrate lyase (ACLY), generating acetyl-CoA and oxalo-
acetate. This acetyl-CoA is used for a number of important meta-
bolic functions, including synthesis of fatty acids, cholesterol,
and nucleotide sugars such as UDP-N-acetylglucosamine.
Acetyl-CoA also serves as the acetyl-group donor for both lysine
and N-terminal acetylation (Carrer and Wellen, 2015; Pietrocola
et al., 2015). ACLY plays an important role in regulating histone
acetylation levels in diverse mammalian cell types (Covarrubias
et al., 2016; Donohoe et al., 2012; Lee et al., 2014; Wellen
et al., 2009).
In addition to ACLY, nuclear-cytosolic acetyl-CoA is produced
from acetate by acyl-CoA synthetase short chain family member
2 (ACSS2) (Luong et al., 2000). Recent studies have revealed an
important role for this enzyme in hypoxia and in some cancers
(Comerford et al., 2014; Gao et al., 2016; Kamphorst et al.,
2014; Mashimo et al., 2014; Schug et al., 2015, 2016; Yoshii
et al., 2009). Acetate can be produced intracellularly by histone
deacetylase reactions or can be imported from the environment
(Carrer and Wellen, 2015). Levels of acetate in circulating blood
are rather low, ranging from 50 to 200 mM in humans, although
acetate concentrations can increase substantially in certain con-
ditions, such as following alcohol consumption, high-fat feeding,
or infection, or in specific locations such as the portal vein
(Balmer et al., 2016; Herrmann et al., 1985; Lundquist et al.,
1962; Perry et al., 2016; Scheppach et al., 1991; Skutches
et al., 1979; Tollinger et al., 1979). Acetate is also exported by
cells under certain conditions, such as low intracellular pH
(McBrian et al., 2013), and thus could potentially be made
available for uptake by other cells in the immediate microenvi-
ronment. Two additional acetyl-CoA-producing enzymes, theports 17, 1037–1052, October 18, 2016 ª 2016 The Authors. 1037
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
PDC and carnitine acetyltransferase (CrAT), have been reported
to be present in the nucleus and to contribute acetyl-CoA for
histone acetylation (Madiraju et al., 2009; Sutendra et al.,
2014). The PDC was shown to translocate from mitochondria
to the nucleus under certain conditions, such as growth factor
stimulation; within the nucleus, the complex is intact and retains
the ability to convert pyruvate to acetyl-CoA (Sutendra et al.,
2014). The relative contributions of each of these enzymes to
the regulation of histone acetylation and lipid synthesis, as well
as the mechanisms of metabolic flexibility between these en-
zymes, are poorly understood.
Whole-body loss of ACLY is early embryonic lethal, indicating
that it serves non-redundant roles during development
(Beigneux et al., 2004). Silencing or inhibition of ACLY sup-
presses the proliferation of many cancer cell lines and impairs tu-
mor growth (Bauer et al., 2005; Hanai et al., 2012; Hatzivassiliou
et al., 2005; Migita et al., 2008; Shah et al., 2016; Zaidi et al.,
2012). Depending on the context, ACLY silencing or inhibition
can also promote senescence (Lee et al., 2015), induce differen-
tiation (Hatzivassiliou et al., 2005), or suppress cancer stemness
(Hanai et al., 2013), further pointing to its potential as a target for
cancer therapy. Inhibition of ACLY in adult animals and humans
is reasonably well tolerated and produces blood lipid-lowering
effects (Ballantyne et al., 2013; Gutierrez et al., 2014; Pearce
et al., 1998). Thus, there may be a therapeutic window for
ACLY inhibition in treatment of cancer and/or metabolic dis-
eases; although the extent to which cells could leverage other
compensatory mechanisms upon reduced ACLY function is
not clear.
In this study, we aimed to elucidate two questions: first,
does use of glucose-derived carbon for fatty acid synthesis
and histone acetylation require ACLY; and second, can cells
compensate for ACLY deficiency and, if so, by which mecha-
nisms or pathways? To address these questions, we gener-
ated a conditional mouse model of Acly deficiency (Aclyf/f
mice), as well as immortalized mouse embryonic fibroblast
(MEF) cell lines (Aclyf/f MEFs). As a complement to these
models, we used CRISPR-Cas9 genome editing to delete
ACLY from human glioblastoma cells. ACLY deficiency in
both MEFs and glioblastoma cells potently impaired prolifera-
tion and suppressed histone acetylation levels. Both lipid syn-
thesis and histone acetylation from glucose-derived carbon
were severely impaired in ACLY-deficient MEFs. Cells partially
compensated for the absence of ACLY by upregulating
ACSS2, and ACLY-deficient MEFs became dependent on
exogenous acetate for viability. Acetate was used to supply
acetyl-CoA for both lipid synthesis and histone acetylation,
although global histone acetylation levels remained low unless
cells were supplemented with high levels of acetate. ACSS2
upregulation in the absence of ACLY was also observed in vivo
upon deletion of Acly from adipocytes in mice. AclyFAT/ mice
exhibited normal body weight and adipose tissue architecture,
and production of acetyl-CoA and malonyl-CoA from acetate
was enhanced in ACLY-deficient adipocytes. Upon deuter-
ated-water (D2O) labeling of wild-type (WT) and Acly
FAT/
mice, we observed that de novo synthesized fatty acids were
present in white adipose tissue (WAT) in both genotypes,
although some differences between depots were apparent.1038 Cell Reports 17, 1037–1052, October 18, 2016Visceral (epididymal) WAT (VWAT) exhibited no significant dif-
ferences between WT and AclyFAT/ mice in quantities of de
novo synthesized fatty acids, while synthesized saturated fatty
acids were reduced in subcutaneous (inguinal) WAT (SWAT) of
AclyFAT/ mice. Histone acetylation levels were also signifi-
cantly altered in AclyFAT/ SWAT. Taken together, this study
demonstrates that ACLY is required for glucose-dependent
fatty acid synthesis and histone acetylation and that a major,
albeit partial, compensatory mechanism for ACLY deficiency
involves engagement of acetate metabolism.RESULTS
Genetic Deletion of Acly in Cells Is Consistent with
Viability but Impairs Proliferation
To facilitate investigation of the role of ACLY in vitro and in vivo,
we generated a conditional mouse model of Acly deficiency,
using a conventional Cre-lox strategy (Aclyf/f mice) (Figure S1A).
MEFs from Aclyf/f mice were immortalized (Aclyf/f MEFs). Acly
was efficiently deleted from Aclyf/f MEFs upon administration
of Cre recombinase (Figure S1B). AclyD/D MEFs continued to
proliferate, although more slowly than parental cells (Fig-
ure S1C). However, over time, these cells regained ACLY
expression, indicating that deletion occurred in less than
100% of cells and that those that retained ACLY had a growth
advantage over AclyD/D cells (Figure S1B). To address this, we
generated three clonal Acly knockout (KO) cell lines, desig-
nated PC7, PC8, and PC9 (Figure 1A). ACSS2 was strikingly
upregulated in these cell lines (Figure 1A). Proliferation in the
absence of ACLY was significantly slower in each of the KO
cell lines than in the parental Aclyf/f cells (Figure 1B). We also
used CRISPR-Cas9 to delete ACLY from LN229 glioblastoma
cells (Figure 1C). ACSS2 levels were high at baseline in
LN229 cells and only modestly increased with ACLY deletion
(Figure 1C). However, similar to the ACLY-deficient MEFs,
ACLY-deficient LN229 clones exhibited a marked proliferative
impairment (Figure 1D).
Two of the ACLY-KO clones, PC7 and PC9, were reconsti-
tuted with wild-type ACLY (ACLY-WT) or a catalytically inactive
ACLY mutant (ACLY-H760A) (Figures 1E and S1D). ACLY-WT,
but not ACLY-H760A, significantly restored proliferation in
the KO clones (Figures 1F and S1E). Of note, despite compa-
rable expression upon initial reconstitution (data not shown),
ACLY-H760A failed to stably express as highly as ACLY-WT
(Figure S1D), further pointing to a strong selective advantage
for cells expressing catalytically active ACLY. ACSS2 levels
were elevated in both the nucleus and cytoplasm of ACLY-
deficient cells, and this was reversed upon reconstitution of
ACLY-WT (Figure 1E).
Next, we inquired whether ACSS2 upregulation was induced
by ACLY deletion or whether growing up ACLY-deficient clones
selected for those that already had high ACSS2 expression. To
test this, we examined the timing of ACSS2 upregulation upon
loss of ACLY function. In Aclyf/f MEFs, ACSS2 was rapidly upre-
gulated in parallel to loss of ACLY protein following Cre adminis-
tration (Figure 1G). Moreover, treatment of MEFs with an ACLY
inhibitor (BMS-303141) led to increased ACSS2 within 96 hr
Figure 1. Genetic Deletion of Acly Is Con-
sistent with Cell Viability but Impairs Prolif-
eration
(A) Western blot of three clonal ACLY-deficient
(KO) cell lines (PC7, PC8, and PC9) generated from
Aclyf/f MEFs.
(B) Proliferation curve of Aclyf/f and ACLY-KO
MEFs over 5 days; mean ± SEM of triplicate wells,
statistical significance compared to Aclyf/f.
(C) Western blot verification of ACLY knockout by
CRISPR-Cas9 in LN229 glioblastoma cells.
(D) Proliferation curve of LN229 and two ACLY-
knockout clonal cell lines over 5 days; error bars
indicate mean ± SEM of triplicate wells, statistical
significance compared to LN229.
(E) Western blot of nuclear and cytoplasmic frac-
tions of Aclyf/f, PC9, and reconstituted ACLY-WT
and ACLY-H760A PC9 cells. FASN and LMNA
(lamin A/C) are cytoplasmic and nuclear markers,
respectively.
(F) Proliferation curve of Aclyf/f MEF and PC9 lines
compared to PC9 reconstituted with ACLY-WT or
ACLY-H760A over 5 days; error bars indicate
mean ± SEM of triplicate wells, statistical signifi-
cance compared to PC9.
(G)Western blot of ACLY and ACSS2 protein levels
in Aclyf/fMEFs over 144 hr following administration
of Cre recombinase.
(H) Western blot of ACLY and ACSS2 protein levels
in Aclyf/f MEFs over 144 hr with pharmacological
inhibition of ACLY (50 mM BMS-303141).
For all panels: **p < 0.01; ***p < 0.001;
****p < 0.0001; n.s., not significant.
See also Figure S1.(Figure 1H). Thus, we conclude that the loss of ACLY activity
induces ACSS2 upregulation.
ACLY-Deficient MEFs Require Use of Exogenous
Acetate for Viability
The amount of acetate in the serum used in these experiments
was quantified by nuclear magnetic resonance (NMR). Undiluted
calf serum (CS) contained 800–900 mM acetate, while acetate
was undetectable in dialyzed fetal bovine serum (dFBS) (Fig-
ures 2A and S2A). Given that acetate was also undetectable in
DMEM, our standard culture conditions (DMEM + 10% CS)
exposed cells to slightly less than 100 mM acetate. ACLY-defi-
cient cells began to die when cultured in the absence of exoge-
nous acetate (DMEM + 10% dFBS) (Figures 2B–2D), and adding
100 mMacetate was sufficient to restore viability (Figures 2C and
2E). No added proliferative benefit was gained by further
increasing the amount of acetate supplemented (Figure 2F).
Additionally, reconstitution of ACLY-WT, but not ACLY-H760A,
restored the ability of KO cells to grow in acetate-depleted
conditions (Figures 2B and 2E). To test whether acetyl-CoA
production by ACSS2 was required for viability, we used
CRISPR-Cas9 to delete Acss2 in Aclyf/fMEFs (Figure S2B). LittleCell Repoto no difference in the proliferation rate
was observed upon Acss2 deletion
when Acly was intact (Figure S2C). How-ever, subsequent deletion of Acly resulted in extensive toxicity
(Figures 2G and S2D), which was not observed in cells express-
ing Acss2, confirming that cells rely on ACSS2 for survival in the
absence of ACLY.
Physiological Levels of Acetate Support Lipid Synthesis
in the Absence of ACLY
ACLY deficiency did not alter rates of glucose or glutamine con-
sumption, although lactate and glutamate production were
elevated (Figure 3A). To confirm the requirement for ACLY for
glucose-dependent fatty acid synthesis and test the use of ace-
tate, we set up parallel stable isotope tracer experiments in
which Aclyf/f, PC9, PC9-ACLY-WT, and PC9-ACLY-H760A cells
were incubated for 48 hr either with [U-13C]glucose (10 mM) and
unlabeled acetate (100 mM) or with [1,2-13C]acetate (100 mM) and
unlabeled glucose (10 mM) (Figure 3B). In ACLY-proficient cells,
palmitate was strongly labeled from glucose-derived carbon, as
expected. In PC9 ACLY-KO cells, labeling of palmitate from
13C-glucose was nearly abolished; this could be restored by
reconstitution of ACLY-WT but not ACLY-H760A (Figure 3C).
Conversely, a marked increase in use of acetate for fatty acid
synthesis was observed in PC9 and PC9-ACLY-H760A cellsrts 17, 1037–1052, October 18, 2016 1039
Figure 2. ACLY-Deficient MEFs Require Exogenous Acetate for Viability
(A) Acetate concentrations in DMEM, RPMI, 100% dialyzed fetal bovine serum (dFBS), and 100% calf serum (CS); error bars indicate mean ± SEM of triplicate
aliquots. See Figure S2A for spectrum. n.d., not detected.
(B) Proliferation curve over 5 days of Aclyf/f, PC9, PC9-ACLY-WT, and PC9-ACLY-H760A cells in acetate-free conditions (DMEM + 10%dFBS + 10mM glucose);
error bars indicate mean ± SEM of triplicate wells.
(C) Image of ACLY-deficient PC9 cells cultured for 5 days in DMEM + 10% dFBS + 10 mM glucose, without (left) or with (right) 100 mM sodium acetate.
(D) Western blot of apoptotic markers cleaved poly(ADP-ribose) polymerase (PARP) and cleaved caspase-3 (CASP3) in Aclyf/f and PC9 cells cultured in acetate-
free conditions (DMEM + 10% dFBS + 10 mM glucose) for 4 (D4) or 5 (D5) days.
(E) Cell numbers following 5 days in culture in DMEM + 10% dFBS + 10 mM glucose alone (black) or supplemented with 100 mM sodium acetate (red) in Aclyf/f,
PC9, PC9-ACLY-WT, and PC9-ACLY-H760A cells; error bars indicate mean ± SEM of triplicates. ***p < 0.001. Dotted line represents cell number at plating.
(legend continued on next page)
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(Figure 3D). We also examined the use of glucose and acetate
carbon for synthesis of HMG (hydroxymethylglutaryl)-CoA, an
intermediate in the mevalonate pathway and ketone body
synthesis. Again, parental and PC9-ACLY-WT cells used
glucose-derived carbon for HMG-CoA synthesis (Figure 3E). In
the absence of ACLY, glucose carbon use for HMG-CoA synthe-
sis was extremely limited (Figure 3E); instead, acetate was used
(Figure 3F). Total levels of HMG-CoA trended slightly lower in the
PC9 cells, though this difference was not statistically significant
(Figure 3G). The data thus show that, in MEFs, glucose-depen-
dent synthesis of fatty acids and HMG-CoA is nearly completely
dependent on ACLY, and a physiological level of acetate can at
least partially support lipid synthesis in its absence.
ACLY Is the Primary Supplier of Acetyl-CoA for
Maintaining Global Histone Acetylation
Histone acetylation is another major fate of nuclear-cytosolic
acetyl-CoA. Consistent with previous data using RNAi-mediated
ACLY silencing (Lee et al., 2014;Wellen et al., 2009), global levels
of histone acetylation were strikingly reduced upon genetic dele-
tion of Acly, despite increased ACSS2. Moreover, although
100 mM acetate was sufficient to restore survival in dFBS-
cultured KO cells, it failed to rescue histone acetylation levels.
However, incubating cells with a high level of acetate (1 mM)
markedly increased histone acetylation levels in KO cells (Fig-
ure 4A). Reciprocally, histone acetylation levels were low in WT
MEFswhen cultured in 1mMglucose and increased with greater
glucose concentrations. In KO cells, histone acetylation levels
were low at all concentrations of glucose tested, up to 25 mM
(Figure S3A). Reconstitution of PC9 cells with ACLY-WT but
not, ACLY-H760A, restored histone acetylation levels to those
in the parental cells (Figure 4A).
To determine the respective use of glucose- and acetate-
derived carbon for histone acetylation in each of the MEF cell
lines, we conducted stable isotope tracer experiments under
three conditions: (1) [U-13C]glucose (10 mM) and unlabeled
acetate (100 mM), (2) physiological [1,2-13C]acetate (100 mM)
and unlabeled glucose (10 mM), or (3) high [1,2-13C]acetate
(1 mM) and unlabeled glucose (10 mM) (Figure S3B). In condition
1, histone acetyl groups were strongly labeled from 13C-glucose
in Aclyf/f and PC9-ACLY-WT cells (Figures 4B, 4E, and S3C). In
PC9 and PC9-ACLY-H760A cells, labeling of histone acetyl
groups from glucose carbon was severely compromised (Fig-
ures 4B, 4E, and S3C). Moreover, aligning with western blot
data, total levels of histone acetylation were lower in cells
lacking functional ACLY (Figure 4E). Thus, the data indicate
that ACLY is required for the majority of glucose-dependent
histone acetylation. In cells lacking functional ACLY (PC9 and
PC9-ACLY-H760A), 100 mM acetate contributed carbon to his-
tone acetylation with 40%–60% of the acetyl groups derived
from acetate after 24-hr labeling (Figure 4C), but total acetylation
remained low (Figures 4F and S3D). In 1 mM 13C-acetate, total(F) Proliferation of PC9 cells over 5 days cultured in DMEM + 10% dFBS + 10mM
of triplicate wells.
(G) Parental Aclyf/f MEFs and two clones of ACSS2-deficient Aclyf/f MEFs were a
western blot after 2 days (+) and 2 weeks (++). See Figure S2D for correspondin
See also Figure S2.histone acetylation levels rose (Figures 4G and S3E), consistent
with western blot data, and acetate carbon constituted the ma-
jority of histone acetyl groups (Figure 4D). These data indicate
that ACLY is the dominant supplier of acetyl-CoA for histone
acetylation in standard, nutrient-rich conditions and that, in its
absence, cells can use acetate to supply acetyl-CoA for histone
acetylation, although high exogenous acetate availability is
needed to bring histone acetylation up to levels matching those
of ACLY-proficient cells. Of note, high acetate did not produce a
corresponding rescue of proliferation (Figure 2F). Thus, while
ACLY-deficient cells exhibit both slower proliferation and lower
histone acetylation levels, histone acetylation can be raised
with high acetate without restoration of normal rates of prolifer-
ation, supporting the notion that metabolism regulates histone
acetylation at least partially independently of proliferation.
We previously defined acetyl-CoA-responsive gene sets in
LN229 glioblastoma cells (Lee et al., 2014). Cell-cycle- and
DNA-replication-related genes were enriched among those
genes that were suppressed in low glucose and increased by
both glucose and acetate, although only glucose impacted
doubling time (Lee et al., 2014). As observed in MEFs, ACLY
deletion in LN229 cells abolished glucose-dependent regulation
of global histone acetylation (Figure S4A). Acetate supplementa-
tion increased histone acetylation in ACLY null LN229 cells in a
dose-dependent manner (Figure S4A). Consistently, the ability
of glucose to promote expression of proliferation-related genes
(E2F2, MCM10, and SKP2) was potently inhibited in ACLY-defi-
cient cells. Expression of these genes exhibited dose-dependent
rescue by acetate (Figure S4B), correlating with global histone
acetylation levels, despite the lack of a proliferation rescue (Fig-
ure S4C). In addition, we were surprised to find that whole-cell
acetyl-CoA levels were minimally impacted in ACLY-KO as
compared to WT LN299 cells in high-glucose conditions
(Figure S4D).
Acetyl-CoA Levels Are Maintained by Acetate in
ACLY-Deficient Cells
In prior studies, global histone acetylation levels have tracked
closely with cellular acetyl-CoA levels (Cai et al., 2011; Cluntun
et al., 2015; Lee et al., 2014). It was, therefore, unexpected to
find these uncoupled in ACLY-KO LN229 cells (Figure S4D).
We further explored this in ACLY-KO MEFs and found that
acetyl-CoA levels were significantly higher in the KO cells than
in the WT Aclyf/f cells when cultured in 10 mM glucose and
100 mM acetate (Figure 5A). These data suggested either that
mitochondrial acetyl-CoA, which is inaccessible for histone acet-
ylation (Takahashi et al., 2006), is elevated in ACLY-KO cells or
that ACSS2 compensation allows plentiful nuclear-cytosolic
acetyl-CoA production from acetate but that this acetate-
derived acetyl-CoA is used less effectively than glucose-derived
acetyl-CoA for histone acetylation. We reasoned that mitochon-
drial and extra-mitochondrial acetyl-CoA pools in ACLY KO cellsglucose, with 100 mMor 1 mM sodium acetate; error bars indicate mean ± SEM
dministered Cre recombinase once (+) or twice (++) and proteins collected for
g images.
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Figure 3. Acetate Supports Lipid Synthesis in the Absence of ACLY
(A) Measurements of glucose consumption and lactate production (left) and glutamine consumption and glutamate production (right), normalized to cell volume
(cell number3mean cell volume); error bars indicate mean ± SEM of triplicate wells; **p < 0.01; ***p < 0.001. Experiment was performed in glucose-free DMEM +
10% dFBS + 10 mM glucose + 100 mM sodium acetate.
(B) Experimental design for heavy isotope labeling of fatty acids using [U-13C]glucose, with unlabeled acetate present (left) and [1,2-13C]acetate, with unlabeled
glucose present (right).
(legend continued on next page)
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could be distinguished based on whether whole-cell acetyl-CoA
is derived from glucose or from acetate (Figure 5B). This is
because, in the absence of ACLY, glucose carbon does not
meaningfully contribute to nuclear-cytosolic acetyl-CoA, as
determined by its minimal use for either lipid synthesis or histone
acetylation (Figures 3 and 4). Within mitochondria, both glucose
(via PDC) and acetate (via mitochondrial acetyl-CoA synthe-
tases) can be used to generate acetyl-CoA for citrate synthesis.
However, as assessed by enrichment of citrate and malate, ac-
etate contributes minimally to mitochondrial metabolism in both
WT and KO cells, while glucose is oxidized in both cell lines
under these conditions (albeit to a somewhat lesser extent in
KO cells) (Figures 5C, 5D, S5A, and S5B). These data suggest
that, in ACLY-KO cells, any glucose-derived acetyl-CoA is mito-
chondrial, whereas acetate-derived acetyl-CoA is predominantly
nuclear cytosolic (Figure 5B). Thus measuring the contribution of
glucose and acetate to whole-cell acetyl-CoA should allow us to
distinguish whether the increase in acetyl-CoA in ACLY-KO
MEFs reflects elevated mitochondrial or extra-mitochondrial
acetyl-CoA.
Therefore, we incubated cells with [U-13C]glucose (10 mM)
and 100 mM unlabeled acetate or, reciprocally, [1,2-13C]acetate
(100 mM) and 10 mM unlabeled glucose. In WT (Aclyf/f) cells, as
expected, acetyl-CoA, malonyl-CoA, and succinyl-CoA were
more strongly enriched from glucose than acetate (Figures 5E–
5G). Interestingly, despite minimal labeling of malonyl-CoA
from acetate in WT cells (consistent with palmitate enrichment
in Figure 3D), 20% of the acetyl-CoA pool was enriched from
13C-acetate (Figures 5E and 5F), further hinting at differential
partitioning of acetate- and glucose-derived acetyl-CoA. In
contrast, in the PC9 ACLY-KO cells, acetyl-CoA was minimally
labeled from glucose, and 80% of the acetyl-CoA pool was
labeled from acetate after 6 hr (Figure 5E). Malonyl-CoA, but
not succinyl-CoA, was also strongly enriched from 13C-acetate
in PC9 cells (Figures 5F and 5G). In sum, these data indicate
that acetate is the major source of acetyl-CoA in the absence
of ACLY, and it appears to predominantly supply the extra-mito-
chondrial pool.
A second implication of these data is that, at least in KO cells,
the mitochondrial acetyl-CoA pool is likely quite low in compar-
ison to the extra-mitochondrial pool, since acetyl-CoA is mini-
mally labeled from glucose-derived carbon. A large difference
in relative acetyl-CoA pool size can explain the apparently para-
doxical finding that, in KO cells, citrate is labeled from glucose,
despite minimal acetyl-CoA enrichment (Figures 5C and 5E).
This interpretation is consistent with findings from a recent study
of the mitochondrial metabolome, which found that matrix(C) Isotopologue distribution of palmitate after 48-hr labeling in 10 mM [U-13C
Expressed as percent enrichment of palmitate (bottom); error bars indicate mea
(D) Isotopologues of palmitate after 48-hr labeling in 100 mM [1,2-13C]acetate in A
enrichment of palmitate (bottom); error bars indicate mean ± SD of triplicates. **
(E) Isotopologues of HMG-CoA upon 6-hr labeling in 10 mM [U-13C]glucose (10
mean ± SD of triplicates.
(F) Isotopologues of HMG-CoA upon 6-hr labeling in 100 mM [1,2-13C]acetate (1
mean ± SD of triplicates.
(G) Total HMG-CoA quantitation in cells cultured in DMEM + 10% dFBS + 10 mM
of triplicates. n.s., not significant.acetyl-CoA levels are very low unless complex I is inhibited,
which increases the NADH/NAD ratio, reducing the activity of
citrate synthase (Chen et al., 2016). Notably, another implication
of this result is that a much larger nuclear-cytosolic acetyl-CoA
pool in cultured cells would explain why whole-cell acetyl-CoA
measurements in ACLY-proficient cells correlate closely with
histone acetylation levels (Cluntun et al., 2015; Lee et al., 2014).
Together, these data indicate that acetate carbon is used to
supply acetyl-CoA for nuclear and cytosolic processes in the
absence of ACLY. Nevertheless, histone acetylation levels
remain low in the absence of ACLY unless a high level of acetate
is supplied, and proliferation remains constrained even in the
presence of high acetate. Thus ACSS2 is a key, but partial,
mechanism of compensation for ACLY deficiency.
ACSS2 Is Upregulated In Vivo upon Deletion ofAcly from
Adipocytes
Finally, we sought to determine whether ACSS2 is upregulated
upon loss of ACLY in vivo. Glucose uptake and glucose-depen-
dent lipid synthesis in adipocytes are closely associated with in-
sulin sensitivity and systemic metabolic homeostasis (Herman
and Kahn, 2006; Herman et al., 2012). Moreover, our prior
work implicated ACLY in regulating histone acetylation levels
and expression of key genes in glucose metabolism, such as
Glut4, in 3T3-L1 adipocytes (Wellen et al., 2009). To interrogate
the role of adipocyte ACLY in vivo, we bred Aclyf/f mice to
Adiponectin-Cre transgenicmice, which express Cre specifically
in adipocytes (Lee et al., 2013). ACSS2 was upregulated in
SWAT and VWAT upon deletion of Acly (Figures 6A and 6B). In
VWAT, ACSS2 upregulation was more apparent at the protein
level than the mRNA level (Figures 6A and 6B). Fatty acid syn-
thase (FASN) protein levels were also elevated in the absence
of ACLY, particularly in SWAT (Figure 6A). Lipid droplets formed
normally in AclyFAT/ adipocytes; in VWAT, adipocytes
were larger than in WT mice, while in SWAT, adipocyte lipid
droplet size was comparable between genotypes (Figure 6C).
Body weight was indistinguishable between WT and AclyFat/
mice fed a regular chow diet (Figure 6D). However, overall
gene expression patterns were altered, with lower expression
of adipocyte genes such as Glut4 in the AclyFAT/ mice
(Figure 6E).
Adipocyte Acetyl-CoA and LipidMetabolism Is Altered in
the Absence of ACLY
These data suggested that acetate metabolism might, at least
partially, compensate for ACLY deficiency in adipocytes in vivo.
Similar to that observed in MEFs, acetyl-CoA levels were higher]glucose in Aclyf/f, PC9, PC9-ACLY-WT, and PC9-ACLY-H760A MEFs (top).
n ± SD of triplicates. **p < 0.01; ***p < 0.001.
clyf/f, PC9, PC9-ACLY-WT, PC9-Acly H760A MEFs (top). Expressed as percent
*p < 0.001; ns, not significant.
0 mM unlabeled acetate present) in Aclyf/f and PC9 MEFs; error bars indicate
0 mM unlabeled glucose present) in Aclyf/f and PC9 MEFs; error bars indicate
glucose + 100 mM sodium acetate (unlabeled); error bars indicate mean ± SEM
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Figure 4. ACLY Is Required for Sustaining Histone Acetylation Levels, despite ACSS2 Compensation
(A) Western blot of acetylated histones extracted from Aclyf/f, PC9, PC9-ACLY-WT, and PC9-ACLY-H760A MEFs cultured in complete medium (DMEM + 10%
CS), dFBSmedium (DMEM + 10%dFBS), +100 mMacetate medium (DMEM + 10%dFBS + 100 mMsodium acetate), and +1mM acetate medium (DMEM + 10%
dFBS + 1 mM sodium acetate) for 48 hr.
(B–D) Fractions of histone H3-K14, -K18, and -K23 acetylation (m+2) derived from 10 mM [U-13C]glucose, with unlabeled 100 mM acetate present (B); 100 mM
[1,2-13C]acetate, with 10 mM unlabeled glucose present (C); or 1 mM [1,2-13C]acetate, with 10 mM unlabeled glucose present (D); error bars indicate mean ±
SEM of triplicate samples. Labeling was for 24 hr (see also Figure S3B for experimental design).
(E–G) Overall percentage of H3K23 acetylated in each cell line (y axis), as well as the relative fraction of this acetylation incorporated from a labeled source (red):
10 mM [U-13C]glucose (E), 100 mM [1,2-13C]acetate (F), and 1 mM [1,2-13C]acetate (G) or unlabeled sources (black); error bars indicate mean ± SEM of triplicate
samples. The same dataset is represented in parts (B–D) and (E–G). See Figures S3C–S3E for overall percentage data on K14 and K18 acetylation.
See also Figures S3 and S4.
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Figure 5. Acetyl-CoA Pools Are Sustained by Acetate in the Absence of ACLY
(A) Relative whole-cell acetyl-CoA levels inAclyf/f and PC9MEFs cultured in glucose-free DMEM+ 10%dFBS + 10mMglucose + 100 mMsodium acetate for 6 hr,
normalized to cellular volume; error bars indicate mean ± SD of triplicates.
(B) Schematic of acetyl-CoA production from glucose and acetate with (top) or without (bottom) ACLY.
(legend continued on next page)
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in both VWAT and SWAT from AclyFAT/ as compared to WT
mice, while liver acetyl-CoA levels were slightly reduced (Fig-
ure 7A). To test whether AclyFAT/ adipocytes supply acetyl-
CoA and dependent biosynthetic processes using acetate, we
isolated primary visceral adipocytes and tested acetate uptake.
Indeed, acetyl-CoA, as well as malonyl-CoA and HMG-CoA,
were more enriched from [1,2-13C]acetate in primary adipocytes
from AclyFAT/ mice as compared to those from WT mice
(Figures 7B–7D).
Next, we investigated the extent to which de novo synthesized
fatty acids were present in adipose tissue in the absence of
ACLY. To capture rates of de novo lipogenesis (DNL) in vivo,
D2O was administered to mice via a bolus injection and subse-
quent addition to drinking water for 3 weeks. At the conclusion
of labeling VWAT, SWAT, and liver were collected, and total
(saponified) fatty acids from each were analyzed by gas chroma-
tography-mass spectrometry (GC-MS). Plasma D2O enrichment
was confirmed to be equivalent between genotypes (Figure S6A).
In both VWAT and SWAT, abundance of the saturated fatty acids
palmitic acid (C16:0) and stearic acid (C18:0) was significantly
reduced (Figures S6B and S6C). Conversely, monounsaturated
fatty acids, oleic acid (C18:1n9), and palmitoleic acid
(C16:1n7), as well as the essential fatty acid linoleic acid
(C18:2n6), were elevated in SWAT from AclyFAT/ mice (Fig-
ure S6B). A slight reduction in palmitic acid was also observed
in liver (Figure S6D). Fractional enrichment of fatty acids was
not significantly different in VWAT between genotypes, although
SWAT exhibited a moderate reduction in palmitic acid fractional
synthesis (Figures S6E and S6F). Fractional synthesis was not
different between genotypes in the liver, except for a small
reduction for palmitoleic acid (Figure S6G).
The relative quantities of de novo synthesized fatty acids pre-
sent in each tissuewere calculated using plasmaD2Oenrichment,
fatty acid labeling, and abundance. Notably, DNL-derived fatty
acids present in WAT may be synthesized in adipocytes or
produced in the liver and transported to fat. In the SWAT of
AclyFAT/ mice, total de novo synthesized palmitic acid and
stearic acid were significantly reduced (Figure 7E). In contrast,
no significant differences in the quantities of DNL-generated fatty
acidsweredetected betweenAclyFAT/ andAclyf/fmice inVWAT
(Figure 7F). Liver DNL was largely unchanged by adipocyte ACLY
deficiency, although a slight reduction in palmitic acid synthesis
was observed (Figure 7G). Since DNL-derived fatty acids were
reduced inSWATofAclyFAT/mice, this depotmaymaintain lipid
droplet size through greater storage of diet-derived fatty acids, as
suggested by elevated levels of linoleic acid (Figure S6B).
Histone acetylation levels were also analyzed. Despite ACSS2
upregulation and elevated acetyl-CoA levels, H3K9ac and
H3K23ac were significantly lower, and H3K18ac trended lower,(C) Isotopologue distribution of citrate after 6-hr incubationwith 10mM [U-13C]gluc
with 10 mM unlabeled glucose present (red), in Aclyf/f (top) or PC9 (bottom) MEF
(D) Isotopologue distribution of malate in the same conditions as (C).
(E–G) m+2 acetyl-CoA (E), malonyl-CoA (F), or succinyl-CoA (G) following 6-hr l
100 mM [1,2-13C]acetate (with 10mM unlabeled glucose present); error bars indica
using Holm-Sidak test.
For all panels: *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S5.
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difference was not observed in VWAT, suggesting that acetate
compensation for ACLY deficiency may be more complete in
this depot or that other factors are dominant in determining
histone acetylation levels (Figure 7I). No differences in histone
H3 acetylation were detected in the liver (Figure 7J). Altogether,
the data suggest that, in vivo, adipocytes lacking ACLY partially
compensate by engaging acetate metabolism.
DISCUSSION
The findings of this study demonstrate that ACLY is required for
the vast majority of glucose-dependent fatty acid syntheses and
histone acetylations under standard culture conditions and that
ACSS2 upregulation and use of acetate carbon is a major mech-
anism of compensation for ACLY deficiency. Additionally, despite
ACSS2 upregulation and higher acetyl-CoA levels, ACLY defi-
ciency results in lower overall histone acetylation levels, slower
proliferation, and altered gene expression patterns. The data sug-
gest that ACLY and ACSS2 likely play distinct roles in the regula-
tion of histone acetylation and gene expression but also indicate
that the potential for metabolic compensation from acetate
should be considered if ACLY is pursued as a therapeutic target.
From a clinical perspective, prior study of PET (positron emis-
sion tomography) imaging in human hepatocellular carcinoma
patients using 11C-acetate and 18F-fluorodeoxyglucose (FDG)
revealed a dichotomy between acetate and glucose uptake.
Patient tumors, or regions within tumors, with high 11C-acetate
uptake demonstrated low 18F-FDG uptake and vice versa. More-
over, tumors with high 18F-FDG uptake were more proliferative
(Yun et al., 2009). These data support the concept that mamma-
lian cells—cancer cells, in particular—possess an intrinsic flexi-
bility in their ability to acquire acetyl-CoA from different sources
to adjust to changing metabolic environments in vivo. Further
elucidation of the mechanisms connecting ACLY and ACSS2,
as well as the differential phenotypes observed downstream of
their activity, could point toward synthetic lethal strategies for
cancer therapy or improved tumor imaging protocols.
In considering the roles of these enzymes in normal physi-
ology, given the importance of GLUT4-dependent glucose
uptake and glucose-dependent fatty acid synthesis for systemic
metabolic homeostasis (Herman and Kahn, 2006; Herman et al.,
2012), deletion of Acly in adipocytes results in a surprisingly mild
phenotype, with no overt metabolic dysfunction observed for
mixed-background mice on a regular chow diet. Nevertheless,
larger adipocytes and reduced expression of genes, such as
Glut4, observed in this model are also characteristic of obesity
and are associated with poorer metabolic function. This
suggests that AclyFAT/ mice may be more susceptible toose, with 100 mMunlabeled acetate present (black) or 100 mM [1,2-13C]acetate
s; error bars indicate mean ± SEM of triplicates.
abeling in 10 mM [U-13C]glucose (with 100 mM unlabeled acetate present) or
te mean ± SEM of triplicates. For (E–G), all statistical comparisons are to Aclyf/f
Figure 6. ACSS2 Is Upregulated In Vivo upon Deletion of Acly from Adipocytes
(A) Western blot of liver, SWAT, and VWAT from Aclyf/f and AclyFAT/ mice.
(B) mRNA expression of Acly and Acss2 in SWAT (left) and VWAT (right) from Aclyf/f and AclyFAT/ mice; error bars indicate mean ± SEM.
(C) Representative SWAT and VWAT histology from male 16-week-old Aclyf/f and AclyFAT/ mice. Scale bars, 100 mm.
(D) Body weight of male Aclyf/f (n = 9) and AclyFAT/ (n = 8) mice; error bars indicate mean ± SD.
(E) Expression of adipocyte genes in SWAT (left) and VWAT (right) from Aclyf/f (n = 8) and AclyFAT/ (n = 7) mice; error bars indicate mean ± SEM.
For all panels: *p < 0.05; **p < 0.01.
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metabolic dysfunction when nutritionally stressed, for example,
with high fructose feeding. Another interesting question is
whether these mice will exhibit exacerbated metabolic pheno-
types under conditions that alter acetate availability in the blood-
stream, such as ethanol consumption or antibiotic treatment.
The differential impact of ACLY on SWAT and VWAT also
warrants further investigation. It is not clear why SWAT, but
not VWAT, exhibits reduced histone acetylation and de novo
fatty acid synthesis, despite evidence for compensatory mech-
anisms such as FASN upregulation. One possible explanation
relates to an overall greater fraction of fatty acids that are de
novo synthesized in SWAT, as compared to VWAT (Figures
S6E and S6F), placing a greater demand for acetyl-CoA. Poten-
tially, in a tissue with a lower DNL rate, acetate may be more
readily able to compensate in both DNL and histone acetyla-
tion. Distribution of fatty acids in AclyFAT/ WAT depots is
also altered; SWAT, in particular, exhibits increased levels of
monounsaturated and essential fatty acids (Figure S6B). Palmi-
toleate, which has been implicated as an insulin-sensitizing
lipokine (Cao et al., 2008), is elevated in ACLY-deficient
SWAT, raising questions about how altered levels of bioactive
lipid species in the absence of ACLY may influence metabolic
phenotypes. More mechanistic work is also clearly needed to
elucidate the relationship between ACLY and gene regulation.
The relationship between global histone acetylation and gene
expression is not entirely consistent between VWAT and
SWAT, possibly reflecting gene regulatory mechanisms that
are specific to ACLY.
A noteworthy observation in this study is that acetyl-CoA and
histone acetylation levels appear to become uncoupled in the
absence of ACLY, suggesting that acetate-derived acetyl-
CoA may not be efficiently used for histone acetylation. Several
possible mechanisms could account for this. First, it may be
that, in MEFs, an insufficient amount of ACSS2 is present in
the nucleus to efficiently drive histone acetylation. ACSS2 has
been found to localize prominently to the nucleus in some con-
ditions (Chen et al., 2015; Comerford et al., 2014; Xu et al.,
2014); thus, investigation of whether acetate more readily con-
tributes to overall histone acetylation levels in these contexts
will be informative. However, potentially arguing against this
possibility, hypoxia promotes ACSS2 nuclear localization (Xu
et al., 2014); yet, although acetate does regulate histone acet-
ylation in hypoxic cells, a high level of acetate (2.5 mM) is
required (Gao et al., 2016). A second possibility is that, within
the nucleus, acetyl-CoA producing enzymes are channeled,
compartmentalized into niches, or sequestered with particular
binding partners. Through such a mechanism, acetylation ofFigure 7. ACLY-Deficient Adipose Tissue Exhibits Depot-Specific Alte
(A) Acetyl-CoA abundance in SWAT, VWAT, and liver in 11-week-old Aclyf/f (n =
(B–D) Primary mature adipocytes were isolated from 12- to 16-week-old Aclyf/f (n
5 mM unlabeled glucose present). Acetyl-CoA (B), malonyl-CoA (C), and HMG-Co
(E–G) Relative quantities of fatty acids synthesized de novo in SWAT (E), VWAT (
mean ± SEM. The # sign indicates not synthesized de novo.
(H–J) Overall histone H3 acetylation levels in 11-week-old SWAT (H), VWAT (I),
mean ± SEM.
For all panels: *p < 0.05; **p < 0.01.
See also Figure S6.specific proteins may be regulated not only by the relevant ace-
tyltransferase but also by a specific acetyl-CoA-producing
enzyme. Consistent with this possibility, acetylation of HIF2a
was shown to be exclusively dependent on ACSS2 as a source
of acetyl-CoA (Chen et al., 2015; Xu et al., 2014). A third possi-
bility is that ACLY-deficient conditions may result in altered
lysine acetyltransferase (KAT) or HDAC (histone deacetylase)
activity. Finally, a fourth possibility is that lower use of
acetyl-CoA for histone acetylation could be a feature of slow
proliferation in the absence of ACLY (i.e., secondary to the pro-
liferation defect). However, prior findings that histone acetyla-
tion is sensitive to glucose availability over a range that did
not impact proliferation (Lee et al., 2014) and that the TCA cycle
(which supplies ACLY substrate citrate) and mitochondrial
membrane potential have distinct and separate roles in regu-
lating histone acetylation and proliferation, respectively (Martı´-
nez-Reyes et al., 2016), as well as data in the present
article showing that histone acetylation can be boosted by
high acetate without a corresponding rescue of proliferation,
argue against this as a sole explanation. Nevertheless, elucida-
tion of the mechanisms that constrain proliferation in the
absence of ACLY could help to definitively address this.
Investigating these possibilities will illuminate whether cells
possess mechanisms to differentially detect ACLY-generated
versus ACSS2-generated acetyl-CoA as well as define the
functional relationship between histone acetylation levels and
cellular functions and phenotypes. Given that ACLY dominates
in nutrient- and oxygen-replete conditions, whereas ACSS2 be-
comes important in nutrient- and oxygen-poor conditions (Gao
et al., 2016; Schug et al., 2015), having mechanisms such as
different acetylation substrates to distinguish between acetyl-
CoA produced by each enzyme could be advantageous to
cells. For example, such mechanisms could potentially cue
cells to grow when ACLY serves as the acetyl-CoA source
and to mediate adaptive responses when ACSS2 is the primary
acetyl-CoA source. The roles of these enzymes in gene re-
gulation appear to be complex, and in-depth analysis of the
respective roles of ACLY and ACSS2 in genome-wide histone
acetylation and acetylation of other protein substrates is
needed to begin addressing these questions.
Recent work has shown that the PDC is present in the nu-
cleus and is able to convert pyruvate to acetyl-CoA for use in
histone acetylation (Sutendra et al., 2014), raising the question
of how the findings of the present study can be aligned with the
described role of nuclear PDC. We suggest two potential
models that are consistent both with our data and with a role
for nuclear PDC in histone acetylation. In the first model,rations in DNL and Histone Acetylation
6) and AclyFAT/ (n = 7) mice.
= 5) and AclyFAT/ (n = 3) mice and labeled with 100 mM [1,2-13C]acetate (with
A (D) enrichment from acetate was analyzed; error bars indicate mean ± SEM.
F), and liver (G) of Aclyf/f (n = 6) and AclyFAT/ (n = 8) mice; error bars indicate
and liver (J) of Aclyf/f (n = 6) and AclyFAT/ (n = 7) mice; error bars indicate
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ACLY is the primary acetyl-CoA producer for regulation of
global levels of histone acetylation, while PDC (and, potentially,
other nuclear acetyl-CoA sources such as CrAT) could partici-
pate in mediating histone acetylation at specific target genes
but not globally. A recent report that PDC forms a complex
with PKM2, p300, and the arylhydrocarbon receptor (AhR) to
facilitate histone acetylation at AhR target genes is consistent
with such a possibility (Matsuda et al., 2015). In the second
model, the role of ACLY in glucose-dependent histone acetyla-
tion regulation could be context dependent, with a larger role
for PDC emerging in certain conditions or cell types. This
possibility is supported by observations that PDC nuclear
translocation is stimulated by conditions such as growth
factor stimulation and mitochondrial stress (Sutendra et al.,
2014). Further investigation will be needed to evaluate these
models.
In sum, this study points to a crucial interplay between glucose
and acetate metabolism to supply the nuclear-cytosolic acetyl-
CoA pool for fatty acid synthesis and histone acetylation. At
the same time, it shows that, despite compensatory mecha-
nisms, ACLY is required for optimal proliferation, and simply
increasing nuclear-cytosolic acetyl-CoA production is insuffi-
cient to fully replace ACLY. This could point to the importance
of ACLY’s other product, oxaloacetate; a build-up of ACLY’s
substrate citrate; deficiencies in anapleurosis and/or mitochon-
drial function upon loss of a major catapleurotic pathway; or a
signaling mechanism that is specific to ACLY. Clearly, more
work is needed both to understand the mechanisms through
which ACLY facilitates cell proliferation and to further define
the ways that cells partition and use acetyl-CoA produced by
different enzymes. The findings of this study raise a number of
important questions for future investigation, as discussed earlier.
They also clarify the importance of ACLY in glucose-dependent
acetyl-CoA production outside of mitochondria and provide key
insights into the mechanisms of metabolic flexibility used for
production of nuclear-cytosolic acetyl-CoA. Understanding
these compensatory mechanisms will be important to consider
for therapeutic targeting of acetyl-CoA metabolic pathways.EXPERIMENTAL PROCEDURES
Generation of Aclyf/f and AclyFAT/ Mice
A Knockout First targeting vector was obtained from the Knockout Mouse
Project (KOMP) that targets exon 9 of Acly (KOMP: 80097), predicted to result
in a truncated protein subject to nonsense-mediated decay. The Knockout
First allele is initially null but can be converted to a conditional floxed allele
upon Flp recombination (Skarnes et al., 2011). Recombinant 129/B6 hybrid
embryonic stem cells (ESCs) were generated in Penn’s Gene Targeting
Core, and blastocysts were injected at Penn’s Transgenic and Chimeric
Mouse Core. Upon acquisition of the chimeric mice, animals were bred to
obtain germline transmission. Aclyf/+ progenies were selected through
sequential breeding with wild-type C57Bl/6J mice (purchased from Jackson
Laboratory) and mice expressing Flp recombinase (B6.Cg-Tg(ACTFLPe)
9205Dym/J, Jackson Laboratory). Finally,Aclyf/fmice were generated by inter-
breeding and selected by genotyping (see the Supplemental Information).
Immortalized Aclyf/f MEFs were generated from these mice (see the Supple-
mental Information). To produce AclyFAT/ mice, Aclyf/f mice were bred to
adiponectin-Cre transgenic mice (stock no: 010803; B6;FVB-Tg(Adipoq-cre)
1Evdr/J, Jackson Laboratory). The University of Pennsylvania’s Institutional
Animal Care and Use Committee (IACUC) approved all animal experiments.1050 Cell Reports 17, 1037–1052, October 18, 2016In Vivo De Novo Lipogenesis
13-week-old male Aclyf/f (n = 6) and AclyFAT/ (n = 7) mice (C57Bl/6 back-
crossed) were injected intraperitoneally (i.p.) with 0.035 mL/g of body weight
of 0.9% NaCl D2O (Sigma-Aldrich). For 3 subsequent weeks, mice were pro-
vided water bottles containing 8% D2O. At the end of 3 weeks, mice were
fasted for 6 hr and sacrificed, and plasma, liver, VWAT, and SWAT were
collected and snap frozen. Plasma from four additional mice (two Aclyf/f and
twoAclyFAT/) that were not given D2Owas used as controls. See the Supple-
mental Information for details of analysis.
Cell Culture and Proliferation Assays
MEFs (generation described in the Supplemental Information) were cultured in
DMEM (GIBCO) supplemented with 10% Cosmic Calf Serum (CS) (HyClone,
SH30087.03, lot number AXA30096). LN229 cells were cultured in RPMI
1640 medium (GIBCO) supplemented with 10% CS (HyClone SH30087.03,
lot number AXA30096) and 2 mM L-glutamine. For experiments using dFBS,
cells were cultured in glucose-free DMEM + 10% dFBS (GIBCO 26400044),
with indicated concentrations of glucose and sodium acetate added. For
proliferation assays, cells were plated in triplicate at the indicated density
and allowed to adhere overnight. Culture medium was changed the following
day, and cells were allowed to proliferate until the indicated days following
plating. Cells were collected and counted on a hemocytometer. Cell lines
used for viral production included Phoenix E and HEK293T cells, which were
purchased from ATCC. Cells were cultured in DMEM + 10% CS and used at
low passage. All cell lines were routinely monitored and confirmed to be free
of mycoplasma.
Acyl-CoA Quantification and Isotopologue Analysis
Acyl-CoA species were extracted in 1 mL 10% (w/v) trichloroacetic acid
(Sigma-Aldrich, catalog #T6399). Isotopologue enrichment analysis to quan-
tify the incorporation of 10 mM [U-13C]glucose and 100 mM [U-13C]acetate
into acyl-CoA thioesters was performed by liquid chromatograpy-mass
spectrometry/high-resolution mass spectrometry (LC-MS/HRMS). For quan-
titation, internal standards containing [13C3
15N1]-labeled acyl-CoAs gener-
ated in pan6-deficient yeast culture (Snyder et al., 2015) were added to
each sample in equal amounts. Samples were analyzed by an Ultimate
3000 autosampler coupled to a Thermo Q Exactive Plus instrument in
positive electrospray ionization (ESI) mode using the settings described
previously (Frey et al., 2016). A more detailed method can be found in the
Supplemental Information.
Statistics
Student’s two-tailed t tests (two-sample equal variance, two-tailed distribution)
were used for analyses directly comparing two datasets except tissue gene
expression and acyl-CoA datasets (Figures 6 and 7), for which Welch’s t test
was used. Significance was defined as follows: *p < 0.05; **p < 0.01;
***p < 0.001; and ****p < 0.0001.
Please also see the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2016.09.069.
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